Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polycystic Ovary Syndrome | 17 | 2017 | 207 | 4.340 |
Why?
|
| Diabetes Mellitus, Type 2 | 11 | 2022 | 1199 | 2.010 |
Why?
|
| Obesity | 12 | 2022 | 979 | 1.880 |
Why?
|
| Insulin Resistance | 12 | 2022 | 373 | 1.660 |
Why?
|
| Metabolic Diseases | 3 | 2018 | 53 | 1.490 |
Why?
|
| Abdominal Fat | 2 | 2018 | 13 | 1.020 |
Why?
|
| Lipoproteins | 3 | 2011 | 137 | 1.020 |
Why?
|
| Subcutaneous Fat | 3 | 2018 | 22 | 1.000 |
Why?
|
| Adipose Tissue | 3 | 2014 | 263 | 0.990 |
Why?
|
| Glucose Intolerance | 2 | 2022 | 99 | 0.900 |
Why?
|
| Blood Glucose | 11 | 2022 | 849 | 0.830 |
Why?
|
| Weight Reduction Programs | 1 | 2022 | 13 | 0.810 |
Why?
|
| Reproduction | 3 | 2017 | 200 | 0.710 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2021 | 218 | 0.710 |
Why?
|
| Metformin | 2 | 2022 | 132 | 0.680 |
Why?
|
| Testosterone | 4 | 2015 | 272 | 0.660 |
Why?
|
| Hypoglycemic Agents | 4 | 2022 | 359 | 0.650 |
Why?
|
| Intra-Abdominal Fat | 2 | 2009 | 32 | 0.630 |
Why?
|
| Energy Metabolism | 2 | 2014 | 287 | 0.620 |
Why?
|
| Adiposity | 2 | 2018 | 76 | 0.610 |
Why?
|
| Insulin | 7 | 2022 | 1162 | 0.590 |
Why?
|
| Glucagon | 1 | 2017 | 113 | 0.550 |
Why?
|
| Pituitary Gland | 2 | 2008 | 120 | 0.530 |
Why?
|
| Hypoglycemia | 1 | 2017 | 110 | 0.520 |
Why?
|
| Hyperandrogenism | 1 | 2015 | 43 | 0.500 |
Why?
|
| Siblings | 4 | 2009 | 106 | 0.440 |
Why?
|
| Pituitary Neoplasms | 2 | 2005 | 69 | 0.430 |
Why?
|
| Body Mass Index | 8 | 2017 | 776 | 0.430 |
Why?
|
| Biomarkers | 4 | 2018 | 1800 | 0.430 |
Why?
|
| CD11c Antigen | 1 | 2012 | 13 | 0.410 |
Why?
|
| Female | 28 | 2021 | 46894 | 0.380 |
Why?
|
| Humans | 37 | 2022 | 90640 | 0.380 |
Why?
|
| Thiazolidinediones | 1 | 2011 | 74 | 0.380 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 726 | 0.370 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2019 | 50 | 0.360 |
Why?
|
| Weight Loss | 3 | 2022 | 235 | 0.360 |
Why?
|
| Metabolic Syndrome | 3 | 2009 | 125 | 0.360 |
Why?
|
| Body Weight | 2 | 2011 | 455 | 0.360 |
Why?
|
| Waist Circumference | 2 | 2009 | 22 | 0.350 |
Why?
|
| Prediabetic State | 2 | 2021 | 38 | 0.340 |
Why?
|
| Hypertriglyceridemia | 1 | 2009 | 69 | 0.310 |
Why?
|
| Hyperamylasemia | 1 | 2008 | 2 | 0.300 |
Why?
|
| Abdomen | 1 | 2009 | 125 | 0.300 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 2008 | 4 | 0.300 |
Why?
|
| Atherosclerosis | 1 | 2011 | 264 | 0.300 |
Why?
|
| Hypothalamus | 1 | 2008 | 79 | 0.290 |
Why?
|
| Inflammation | 2 | 2015 | 990 | 0.290 |
Why?
|
| Insulin-Secreting Cells | 2 | 2010 | 428 | 0.290 |
Why?
|
| Young Adult | 7 | 2021 | 6426 | 0.290 |
Why?
|
| Adult | 16 | 2022 | 26953 | 0.280 |
Why?
|
| Mothers | 2 | 2009 | 145 | 0.260 |
Why?
|
| Glucose Tolerance Test | 3 | 2021 | 232 | 0.240 |
Why?
|
| Sleep | 2 | 2019 | 457 | 0.240 |
Why?
|
| Sella Turcica | 1 | 2005 | 17 | 0.240 |
Why?
|
| Dyslipidemias | 1 | 2006 | 107 | 0.240 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 92 | 0.240 |
Why?
|
| Cysts | 1 | 2005 | 106 | 0.220 |
Why?
|
| Hyperaldosteronism | 1 | 2003 | 12 | 0.220 |
Why?
|
| Cushing Syndrome | 1 | 2003 | 24 | 0.220 |
Why?
|
| Pheochromocytoma | 1 | 2003 | 49 | 0.210 |
Why?
|
| Shock, Septic | 1 | 2004 | 105 | 0.210 |
Why?
|
| Adenoma | 1 | 2005 | 250 | 0.200 |
Why?
|
| Gastroplasty | 1 | 2022 | 26 | 0.200 |
Why?
|
| Hydrocortisone | 1 | 2004 | 302 | 0.200 |
Why?
|
| Case-Control Studies | 3 | 2012 | 1873 | 0.190 |
Why?
|
| Phenotype | 6 | 2012 | 2473 | 0.190 |
Why?
|
| Adolescent | 6 | 2021 | 9354 | 0.180 |
Why?
|
| Middle Aged | 11 | 2021 | 26347 | 0.180 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 344 | 0.170 |
Why?
|
| Cholesterol, LDL | 2 | 2015 | 228 | 0.170 |
Why?
|
| Incretins | 1 | 2019 | 14 | 0.160 |
Why?
|
| Bone Remodeling | 1 | 2019 | 22 | 0.160 |
Why?
|
| Male | 14 | 2021 | 42967 | 0.160 |
Why?
|
| Androgens | 2 | 2011 | 175 | 0.160 |
Why?
|
| Glucose | 2 | 2021 | 635 | 0.160 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 54 | 0.160 |
Why?
|
| Thyroid Neoplasms | 1 | 2003 | 428 | 0.150 |
Why?
|
| Microfilament Proteins | 2 | 2012 | 211 | 0.150 |
Why?
|
| Body Fat Distribution | 1 | 2018 | 13 | 0.150 |
Why?
|
| Overweight | 2 | 2019 | 118 | 0.150 |
Why?
|
| Bone and Bones | 1 | 2019 | 273 | 0.140 |
Why?
|
| Glucose Clamp Technique | 1 | 2017 | 41 | 0.140 |
Why?
|
| Body Composition | 1 | 2017 | 71 | 0.140 |
Why?
|
| Prevalence | 3 | 2012 | 1251 | 0.130 |
Why?
|
| Postmenopause | 1 | 2017 | 102 | 0.130 |
Why?
|
| Hormones | 1 | 2017 | 139 | 0.130 |
Why?
|
| Risk | 1 | 2018 | 656 | 0.130 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 201 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 982 | 0.130 |
Why?
|
| Chicago | 2 | 2012 | 1441 | 0.130 |
Why?
|
| Aged | 6 | 2019 | 19424 | 0.130 |
Why?
|
| Lipolysis | 1 | 2015 | 23 | 0.120 |
Why?
|
| Triglycerides | 1 | 2015 | 235 | 0.120 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 171 | 0.120 |
Why?
|
| Age Factors | 3 | 2008 | 1871 | 0.110 |
Why?
|
| Child | 2 | 2021 | 7219 | 0.100 |
Why?
|
| Waist-Hip Ratio | 2 | 2009 | 20 | 0.100 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2012 | 29 | 0.100 |
Why?
|
| Adiponectin | 1 | 2011 | 20 | 0.100 |
Why?
|
| Molecular Weight | 1 | 2011 | 332 | 0.100 |
Why?
|
| Nuclear Family | 2 | 2009 | 93 | 0.100 |
Why?
|
| Sulfonylurea Compounds | 1 | 2011 | 66 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 204 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2012 | 728 | 0.080 |
Why?
|
| Blood Pressure | 3 | 2009 | 906 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2012 | 4348 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 388 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2670 | 0.080 |
Why?
|
| Lipoproteins, VLDL | 1 | 2008 | 37 | 0.080 |
Why?
|
| Risk Factors | 2 | 2012 | 5583 | 0.080 |
Why?
|
| Neurosecretory Systems | 1 | 2008 | 36 | 0.070 |
Why?
|
| Lipoproteins, LDL | 1 | 2008 | 88 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2019 | 2891 | 0.070 |
Why?
|
| Pennsylvania | 1 | 2008 | 96 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 196 | 0.070 |
Why?
|
| Lipoproteins, HDL | 1 | 2008 | 97 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2007 | 59 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2009 | 591 | 0.070 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1727 | 0.070 |
Why?
|
| Comorbidity | 1 | 2011 | 955 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 427 | 0.070 |
Why?
|
| Reference Values | 1 | 2008 | 662 | 0.070 |
Why?
|
| Sex Characteristics | 1 | 2009 | 328 | 0.070 |
Why?
|
| Menstruation | 1 | 2006 | 35 | 0.070 |
Why?
|
| Homeostasis | 1 | 2008 | 425 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 569 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2006 | 143 | 0.060 |
Why?
|
| Family Health | 1 | 2005 | 162 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 1074 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2005 | 153 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1738 | 0.060 |
Why?
|
| Animals | 4 | 2019 | 27715 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2012 | 2338 | 0.060 |
Why?
|
| APACHE | 1 | 2004 | 22 | 0.060 |
Why?
|
| Patient Selection | 1 | 2008 | 682 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 1229 | 0.060 |
Why?
|
| Genital Diseases, Female | 1 | 2003 | 24 | 0.060 |
Why?
|
| Prognosis | 1 | 2011 | 3813 | 0.050 |
Why?
|
| Endocrine Surgical Procedures | 1 | 2003 | 3 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 72 | 0.050 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2003 | 28 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2409 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 360 | 0.050 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2002 | 3 | 0.050 |
Why?
|
| Myoblasts | 1 | 2002 | 32 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 5366 | 0.050 |
Why?
|
| Caspases | 1 | 2002 | 155 | 0.050 |
Why?
|
| Genetic Linkage | 1 | 2003 | 624 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 898 | 0.050 |
Why?
|
| Critical Illness | 1 | 2004 | 315 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 6816 | 0.040 |
Why?
|
| Fibrillins | 2 | 2012 | 2 | 0.040 |
Why?
|
| Length of Stay | 1 | 2004 | 757 | 0.040 |
Why?
|
| Adipokines | 1 | 2019 | 17 | 0.040 |
Why?
|
| Jet Lag Syndrome | 1 | 2019 | 13 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2006 | 776 | 0.040 |
Why?
|
| Fertility | 1 | 2019 | 116 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2705 | 0.040 |
Why?
|
| Mice | 2 | 2010 | 11949 | 0.040 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 118 | 0.040 |
Why?
|
| Bone Density | 1 | 2019 | 214 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 300 | 0.040 |
Why?
|
| Circadian Rhythm | 1 | 2019 | 305 | 0.030 |
Why?
|
| Alleles | 2 | 2012 | 1138 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2002 | 1553 | 0.030 |
Why?
|
| Pregnancy | 1 | 2003 | 3070 | 0.030 |
Why?
|
| Apoptosis | 1 | 2002 | 1725 | 0.030 |
Why?
|
| Genotype | 2 | 2012 | 1855 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2010 | 38 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 200 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 260 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 3698 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 207 | 0.020 |
Why?
|
| Spleen | 1 | 2010 | 433 | 0.020 |
Why?
|
| Fathers | 1 | 2009 | 72 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 3431 | 0.020 |
Why?
|
| Cell Movement | 1 | 2010 | 793 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 8379 | 0.020 |
Why?
|
| Amenorrhea | 1 | 2006 | 28 | 0.020 |
Why?
|
| Radioisotopes | 1 | 2006 | 43 | 0.020 |
Why?
|
| Hirsutism | 1 | 2006 | 61 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2006 | 82 | 0.020 |
Why?
|
| Exons | 1 | 2007 | 453 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 303 | 0.020 |
Why?
|
| Family | 1 | 2007 | 324 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 1074 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 340 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2002 | 33 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2002 | 162 | 0.010 |
Why?
|
| DNA | 1 | 2007 | 1314 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 697 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 651 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2002 | 473 | 0.010 |
Why?
|
| Cell Line | 1 | 2002 | 2505 | 0.010 |
Why?
|